Literature DB >> 6190090

Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody.

J W Forstrom, K A Nelson, G T Nepom, I Hellström, K E Hellström.   

Abstract

Idiotypic networks regulate the immune response to a variety of antigens. Antibodies generated against other antibodies, called anti-idiotypic antibodies, can themselves mimic antigen and elicit a specific immune response. They have been shown to induce delayed-type hypersensitivity (DTH) to model antigens in the mouse. As anti-idiotypic antibodies are thought to be involved in the response to tumour-associated antigens we tested whether injection of monoclonal antibodies derived from mice hyperimmunized to a syngeneic, chemically induced sarcoma could mimic antigen and induce DTH to the sarcoma in naive mice. One of the monoclonal antibodies, 4.72, primed BALB/c mice for DTH to the sarcoma but not for DTH to another sarcoma or to sheep erythrocytes. Antibody 4.72 did not induce DTH in mice of immunoglobulin allotype congeneic strains nor did it bind to the sarcoma cells. As antibodies specific for this sarcoma have not been detected, we do not know whether idiotype on immunoglobulin molecules is recognized by antibody 4.72. However, as the response induced by antibody 4.72 was both antigen-specific and allotype-restricted, analogous to those induced by anti-idiotypic antibodies in other systems, we propose that antibody 4.72 is an anti-idiotypic antibody.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190090     DOI: 10.1038/303627a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  12 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

2.  Polyclonal anti-idiotypic antibodies mimicking the small cell lung carcinoma antigen cluster-5A interact with a panel of antibodies and induce specific immune response in animals.

Authors:  C Zwicky; R A Stahel; H Jaksche; R Waibel; H P Lehmann; H Loibner
Journal:  Br J Cancer Suppl       Date:  1991-06

3.  Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.

Authors:  S L Hu; G D Plowman; P Sridhar; U S Stevenson; J P Brown; C D Estin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

Review 4.  Anti-idiotypic antibodies and the induction of specific tumor immunity.

Authors:  G T Nepom; K E Hellström
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 5.  Monoclonal antibodies: implications for virology. Brief review.

Authors:  K C McCullough
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

6.  Uses of monoclonal antibodies: 1983.

Authors:  P A LeBlanc
Journal:  Surv Immunol Res       Date:  1984

7.  Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge.

Authors:  P L Dunn; C A Johnson; J M Styles; S S Pease; C J Dean
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

8.  Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice.

Authors:  G T Nepom; K A Nelson; S L Holbeck; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Monoclonal antiidiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity.

Authors:  V K Lee; T G Harriott; V K Kuchroo; W J Halliday; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

10.  Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine.

Authors:  K A Foon; M Chakraborty; W J John; A Sherratt; H Köhler; M Bhattacharya-Chatterjee
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.